Celemics Inc is a Korea-based company mainly engaged in manufacturing products related to life science medicine. The Company mainly develops and sells target capture kit products. In addition, the Company is engaged in immune repertoire analysis solutions and next-generation sequencing solutions. The Company sells its products in domestic and overseas markets.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
18/06/26	14,180.00 ₩	-0.77%	51,093
17/06/26	14,290.00 ₩	0.00%	19,153
16/06/26	14,290.00 ₩	-2.66%	42,189
15/06/26	14,680.00 ₩	-3.86%	59,865
12/06/26	15,270.00 ₩	+0.66%	21,796

End-of-day quote Korea S.E.

More quotes

Income Statement and Estimates

More financial data

Annual profits - Rate of surprise

Company calendar

End-of-day quote Korea S.E. Other stock markets 18/06/2026			5-day change	1st Jan Change
14,180.00 ^KRW	-0.77%		-5.66%	+422.28%

29/05	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
30/04	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI

Market Cap	139B 91.74M 79.14M 72.76M 68.48M 129M 8.66B 130M 862M 336M 4.25B 344M 337M 14.7B	P/E 2024	2.19x	P/E 2025	-5.49x
Enterprise Value	133B 88.08M 75.98M 69.86M 65.75M 124M 8.31B 125M 828M 322M 4.08B 331M 324M 14.11B	EV / Sales 2024	2.56x	EV / Sales 2025	2.88x
Free-Float	84.27%	Yield 2024 *	-	Yield 2025	-

29/05	Celemics, Inc. announced that it has received KRW 11.5999945 billion in funding	CI
30/04	Celemics, Inc. announced that it has received KRW 8.292707441 billion in funding	CI
28/04	Celemics, Inc. announced that it has received KRW 14.7 billion in funding	CI
31/03	Celemics, Inc. announced that it expects to receive KRW 11.5999945 billion in funding	CI
30/03	Celemics, Inc. announced that it expects to receive KRW 27 billion in funding	CI
13/03	Park Jong-gap completed the acquisition of an additional 5.27% stake in Celemics, Inc. from Kim Hyo-gi, Lee Yong-hoon.	CI
03/02	Celemics, Inc. announced that it expects to receive KRW 9.2927074 billion in funding	CI
03/02	Park Jong-gap agreed to acquire an additional 5.27% stake in Celemics, Inc. from Hyo-gi Kim, Yong-hoon Lee for KRW 2.6 billion.	CI
19/09/22	Celemics, Inc.(KOSDAQ:A331920) dropped from S&P Global BMI Index	CI
22/03/21	Celemics, Inc.(KOSDAQ:A331920) added to S&P Global BMI Index	CI
21/08/20	Celemics, Inc. has completed an IPO in the amount of KRW 26.4 billion.	CI
18/03/20	Celemics, Inc. has filed an IPO.	CI
09/10/15	Celemics Announces Expansion into North America with the Commencement of Celemics America, Inc	CI

1 week	-4.92%
Current month	-16.38%
1 month	+9.92%
3 months	+108.61%
6 months	+397.04%
Current year	+426.34%

Celemics, Inc. Stock

Stocks

A331920

KR7331920009

Biotechnology & Medical Research

Valuation: Celemics, Inc.

Chart: Celemics, Inc.

Latest news : Celemics, Inc.

Press Releases: Celemics, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Celemics, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Annual profits - Rate of surprise

1 week	14,000	16,190
1 month	12,500	18,240
Current year	2,580	19,840
1 year	2,535	19,840
3 years	2,535	19,840
5 years	2,535	22,350
10 years	2,535	39,400

Manager	Title	Age	Since
Yong-Hun Lee CEO	Chief Executive Officer	61	01/01/2017
Hyo-Gi Kim CEO	Chief Executive Officer	43	01/01/2013
Sang-Seok Lee PRN	Corporate Officer/Principal	45	01/01/2020

Director	Title	Age	Since
Hyo-Gi Kim BRD	Director/Board Member	43	01/01/2013
Yong-Hun Lee BRD	Director/Board Member	61	01/01/2017
Sang-Seok Lee BRD	Director/Board Member	45	01/01/2020

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELEMICS, INC.	0.00%	-4.92%	+350.79%	+212.35%	92.45M
LONZA GROUP AG	-0.30%	-0.06%	-12.13%	-10.44%	43.44B
REVOLUTION MEDICINES, INC.	+1.20%	+7.08%	+300.20%	+522.27%	33.54B
IQVIA HOLDINGS INC.	-4.20%	-9.07%	+6.48%	-23.40%	28.48B
BEONE MEDICINES AG	+2.25%	+3.05%	+6.10%	+40.01%	29.2B
CELLTRION, INC.	+0.06%	+4.36%	+13.31%	+21.11%	25.34B
ASCENDIS PHARMA A/S	+0.30%	+8.08%	-	-	14.36B
MEDPACE HOLDINGS, INC.	-1.29%	-4.52%	+49.86%	+101.35%	13.05B
EUROFINS SCIENTIFIC SE	+0.54%	-2.27%	+3.93%	+4.80%	12.67B
IONIS PHARMACEUTICALS, INC.	-0.35%	+0.19%	+99.84%	+80.08%	12.28B
Average	-0.17%	+0.61%	+90.93%	+105.35%	21.25B
Weighted average by Cap.	-0.16%	+1.35%	+61.59%	+103.42%

	2024	2025
Net sales	6.72B 4.44M 3.83M 3.52M 3.31M 6.22M 419M 6.28M 41.7M 16.24M 206M 16.65M 16.3M 711M	5.77B 3.81M 3.29M 3.02M 2.84M 5.34M 359M 5.39M 35.8M 13.94M 176M 14.29M 13.99M 610M
Net income	12.27B 8.1M 6.99M 6.42M 6.05M 11.36M 764M 11.46M 76.14M 29.64M 375M 30.4M 29.75M 1.3B	-4.04B -2.67M -2.3M -2.11M -1.99M -3.74M -252M -3.77M -25.05M -9.75M -123M -10M -9.79M -427M
Net Debt	-9.55B -6.3M -5.44M -5M -4.71M -8.84M -595M -8.92M -59.26M -23.07M -292M -23.66M -23.16M -1.01B	-5.54B -3.66M -3.16M -2.9M -2.73M -5.13M -345M -5.18M -34.39M -13.39M -169M -13.73M -13.44M -586M